News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (16 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (41 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 297 of 400 items have one.
J&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveShingles vaccine most promising common drug to potentially prevent Alzheimer's
A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.
Why it matters: A new study identified three existing medications, including the shingles vaccine, that could be repurposed to treat or prevent Alzheimer's disease.
Read at Medical Xpress → Archived copy (19 Nov 2025), Internet ArchiveProtective microglia subtype offers potential therapeutic pathway in Alzheimer's disease
In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and aggressors, shaping how the disease progresses.
Read at Medical Xpress → Archived copy (15 Nov 2025), Internet ArchiveAlzheon's Alzheimer's Pill Fails in Phase III Trial
Alzheon's oral drug valiltramiprosate missed the primary endpoint in its 325-patient APOLLOE4 Phase 3 trial of early Alzheimer's patients with two copies of the APOE4 gene, though a prespecified mild cognitive impairment subgroup showed larger cognitive and functional benefits.
Why it matters: Another setback for a non-antibody, oral approach to Alzheimer's treatment, though the positive subgroup signal could still support a narrower regulatory path.
Free to read? Not known for this outlet.
Read at Clinical Trials Arena → Archived copy (17 Jun 2026), Internet ArchiveNew drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
A new drug targeting synaptic resilience shows potential in treating Alzheimer’s disease in an NIA-funded study, with early trials indicating safety and possible brain damage reduction. Further research is needed on the drug’s long-term effects.
Why it matters: An NIA-funded study shows a new Alzheimer's drug candidate targeting synaptic resilience is well tolerated in early trials and may reduce brain damage.
Follow new items in a feed reader: Atom feed.
Last updated